BUND FINANCE › Stocks › SYK
Stryker Corporation (SYK)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:02 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +8.50% above its 50-day average.
- It is -1.01% below its 200-day average (long-term downtrend).
- It sits at 42% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$17.1B | US$18.4B | US$20.5B | US$22.6B | US$25.1B |
| Net income | US$2.0B | US$2.4B | US$3.2B | US$3.0B | US$3.2B |
| EPS (diluted) | 5.22 | 6.17 | 8.25 | 7.76 | 8.40 |
| Gross margin | 62.6% | 59.8% | 61.0% | 64.4% | 64.0% |
| Operating margin | 22.0% | 20.2% | 20.9% | 16.3% | 19.5% |
| Net margin | 11.7% | 12.8% | 15.4% | 13.3% | 12.9% |
| Free cash flow | US$2.7B | US$2.0B | US$3.1B | US$3.5B | US$4.3B |
| Total debt | US$12.9B | US$13.5B | US$13.5B | US$14.1B | US$16.4B |
| Cash | US$2.9B | US$1.8B | US$3.0B | US$3.7B | US$4.0B |
Compound annual growth: revenue 10.1% · net income 13.0% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 33.9x | 42.6x | 27.1x |
| EV / EBITDA | 20.1x | 25.8x | 16.5x |
| Operating margin | 21.3% | — | 3.6% |
| Net margin | 13.8% | — | -0.0% |
| Debt / equity | 1.01 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopi…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice